Forecast
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, ASLAN Pharmaceuticals Ltd ADR had revenue of €10.86M and net profit of -€40M
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 10.86M | - |
| Gross profit | 10.54M | 3,507.96% |
| Net profit | -40M | 16.49% |
| EBITDA | -35.64M | 19.12% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €708.23M |
Number of shares | 1.3B |
52-week high/low | €15.53 - €0.43 |
| Dividends | No |
Beta | 1.40 |
P/E ratio | -0.06 |
PEG ratio | 0.00 |
P/B ratio | -0.19 |
P/S ratio | 64.76 |
Company profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
| Name | ASLAN Pharmaceuticals Ltd ADR |
| CEO | Carl Alan Jason Morton Firth EMBA, |
| Headquarters | Singapore,
Singapore |
| Website | |
| Industry | Chemicals |
| IPO | 05/04/2018 |
| Employees | 35 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ASLN |